Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Automated mini-invasive surgical approach to the treatment of mitral insufficiency

Project description

Minimally invasive treatment of heart valves

The heart has four chambers and pumps blood through an equal number of valves, which prevent the backward flow of blood. Insufficiency of the mitral valve, which is located between the left atrium and the left ventricle, usually affects the elderly and is treated with open-heart surgery. The EU-funded MITrep project has developed a device that can assist in the laparoscopic surgery of leaky mitral valves by attaching a polyester ring to the affected valve via a catheter. The approach is suitable for older patients and requires no intensive care stay or lengthy hospitalisation. Importantly, the device has the potential to be used for the repair of the other valves in the future.

Objective

Mitral valve insufficiency is a heart condition, where blood is abnormally leaking out of the mitral valve. This condition mainly afflicts the elderly patients:
- 80% of patients aged 80+ show moderate symptoms (chronic fatigue, shortness of breath, palpitations, racing heart rate)
- 10% of patients above 75 with severe symptoms are at risk of a sudden death (stroke) within 5 years.
- Prevalence will double by 2030.
Mitral insufficiency is treated with open heart surgery (300,000 operations/year in the EU and the USA) followed by intensive care. But this operation is unbearable for fragile patients. Half of the patients above 75 are tagged inoperable because of their age.
Less invasive repair surgeries have been tested (annuloplasty by transfemoral surgery) but lack efficiency and safety and require highly skilled surgeons (not available in each hospital).
In this context, the company CMI’nov has developed MITrep, the first patented mini-invasive surgical device that automatically goes to the mitral valve with no trial and error to affix a leak-preventing ring on the valve.
It uses the transapical approach. Once the ring is anchored, the mitral valve returns to normal activity. No heavy post-surgery effects are expected. No intensive care required.

MITrep can be used by any surgeons : no need to be a mitral valve specialist. It will allow to halve the operation time (from 5 hours to less than 2 hours), reduce hospitalization time to 3 days (vs 5-8 days with 2 days in ICU) and cost about three times less than open heart surgery (30k€ vs 80+k€). It means a dramatic cost reduction for healthcare systems and a real improvement of the care of the elderly patient.

This project holds the ambition to build a new gold standard in valvuloplasty worldwide, starting with mitral repair and replicable to aortic and tricuspid valve repair. It is also a value driver for CMI’nov.
The Phase 1 project will validate the feasibility of MITrep before scale-up and deployment.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

CMI NOV
Net EU contribution
€ 50 000,00
Address
BATIMENT 4 PUISSANCE 3 ZA CHAVANON
43120 MONISTROL SUR LOIRE
France
SME
Yes
Region
Auvergne-Rhône-Alpes Auvergne Haute-Loire
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00